Evidence map›Paper›PMID 36046047›Full record

ArticleFrontiers in oncology2022

Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer.

Steven K Montalvo, Boyu Meng, Mu-Han Lin, Chunjoo Park, Neil B Desai, Raquibul Hannan, Aurelie Garant

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Steven K MontalvoDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Boyu MengDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Mu-Han LinDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Chunjoo ParkDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Neil B DesaiDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Raquibul HannanDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
Aurelie GarantDepartment of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States.
The University of Texas Southwestern Medical Center · USHarold C. Simmons Comprehensive Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adaptive radiotherapy has the potential to reduce margins, improve target coverage, and decrease toxicity to organs at risk (OARs) by optimizing radiation delivery to daily anatomic changes. Salvage for locally recurrent prostate cancer after definitive radiation remains a challenging clinical scenario given the risks to normal tissue in a setting of re-irradiation. Here, we present a case series of five patients with locally recurrent prostate cancer treated with an adaptive online linear accelerator or a 3-T MR-based linear accelerator to demonstrate excellent target coverage. All patients completed the planned treatment course with acceptable acute toxicities but a short follow-up time does not inform subacute/late toxicities.

Indexed as

ablativeadaptiveMR-guidedprostateradiationsalvagestereotactic

Identifiers

PMID36046047
PMCPMC9420944
OpenAlexW4291378279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.